PepGen is empowering nucleic acid therapeutics to go the distance.
PepGen empowers nucleic acid therapeutics to go the distance. PepGen's ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of their innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides, and they are advancing novel conjugate therapeutics to the clinic.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 5, 2021 | Series Unknown | $112.50M | 1 | — | — | Detail |
Dec 9, 2020 | Series A | $45M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
CureDuchenne Ventures | — | Series Unknown |